Sartorius Stedim Biotech (Sartorius Stedim Biotech) Net Income From Continuing Operations : $433 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sartorius Stedim Biotech Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sartorius Stedim Biotech's net income from continuing operations for the three months ended in Dec. 2023 was $63 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $433 Mil.

Sartorius Stedim Biotech Net Income From Continuing Operations Historical Data

The historical data trend for Sartorius Stedim Biotech's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Net Income From Continuing Operations Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

352.69

560.46

730.73

1,197.46

437.41

Sartorius Stedim Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															255.40	159.10	172.16	37.89	63.36

Sartorius Stedim Biotech Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $433 Mil.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

SRTOY:USA DIM:Mexico DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.